Guardian Partners Inc. Makes New $13.53 Million Investment in Johnson & Johnson (NYSE:JNJ)

Guardian Partners Inc. purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 95,125 shares of the company's stock, valued at approximately $13,533,000. Johnson & Johnson makes up about 1.4% of Guardian Partners Inc.'s investment portfolio, making the stock its 21st largest position.

Several other institutional investors have also recently bought and sold shares of JNJ. KLP Kapitalforvaltning AS bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $151,535,000. AXQ Capital LP bought a new position in Johnson & Johnson in the 4th quarter worth approximately $1,537,000. Umpqua Bank boosted its position in Johnson & Johnson by 8.9% in the 4th quarter. Umpqua Bank now owns 20,555 shares of the company's stock valued at $2,975,000 after buying an additional 1,688 shares during the last quarter. Intellus Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $586,000. Finally, Sei Investments Co. raised its position in shares of Johnson & Johnson by 6.0% during the fourth quarter. Sei Investments Co. now owns 1,210,211 shares of the company's stock worth $175,021,000 after acquiring an additional 67,981 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have issued reports on JNJ. Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $171.33.

Johnson & Johnson Stock Down 1.3 %

Shares of JNJ stock traded down $2.15 on Tuesday, hitting $161.14. 7,455,754 shares of the stock were exchanged, compared to its average volume of 7,085,886. The business has a 50-day moving average of $157.70 and a 200 day moving average of $156.14. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a market capitalization of $388.32 billion, a P/E ratio of 24.23, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business's revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.29 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.08%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.